Cronos Group Inc.

NASDAQ:CRON

Drug Manufacturers - Specialty & Generic

Healthcare
$3.17 -0.56%

-$0.02 today

Market cap
$1.16B
Beta
1.25
P/E (TTM)
-488.3
EPS (TTM)
-$0.01
52W Low $1.84High $3.43

Volume 1.13M

Average 1.51M

CRON Operating Cash Flow

Cash generated by the company's core business operations during the period.

Cronos Group Inc.NASDAQ: CRON

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow turns positive

Q1 FY2026 operating cash flow was $10.75M, compared with -$2.1M a year earlier. Trailing-twelve-month operating cash flow was $38.91M.

Context

  • Operating cash flow amounted to 17.6% of revenue in FY2025, up 1.6 pp from a year earlier.
  • Operating cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly operating cash flow holds near $10.75M or moves back toward the trailing-twelve-month quarterly average of $9.73M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.75M-10.7% QoQ
Last fiscal yearDec 2025
$26.32M+39.7% YoY
LTMMar 2026
$38.91M+105.3% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+612.7%——
1 year+39.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
26.32M USD
Year-over-year change
+39.7%

Operating Cash Flow vs competitors

How CRON compares with its peers on the latest reported figures

  • CRON's LTM Mar 2026 operating cash flow of $38.91M is the 10th largest of the 11 companies compared; the peer median is $85.58M.
  • Its year-over-year change of +105.3% is the 4th highest of 11, against a peer median of +36.2%.
  • Operating cash flow amounts to 18.9% of revenue for CRON, versus a peer median of 41.6%.
CRON Competitors Peer median
Operating Cash Flow for CRON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$379.31M +264.6%+16.0%54.0%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$331.04M +66.8%+38.4%41.6%
EMBCEmbecta Corp.LTM Mar 2026$213.5M +318.6%-22.5%20.5%
XNCRXencor, Inc.LTM Jun 2026$205.81M +53.4%—196.1%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$172.07M +328.1%——
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$168.88M -12.6%+20.5%23.4%
PCRXPacira BioSciences, Inc.LTM Mar 2026$142.22M -19.1%+1.5%19.4%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$97.49M -65.5%+4.4%47.6%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$80.3M +19.0%+199.9%401.5%
CRONCronos Group Inc.LTM Mar 2026$38.91M +105.3%—18.9%
IRMDIRadimed CorporationLTM Mar 2026$28.94M +11.2%+35.4%33.5%
Peer median (excluding CRON) $85.58M+36.2%+18.3%41.6%

Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(397.2M)(168.73M)(74.55M)40.02M(2.93M)
Depreciation & Amortization15.4M13.12M8.11M9.34M14.48M
Deferred Income Tax00000
Stock-Based Compensation10.15M15.12M8.77M8.7M7.05M
Change in Working Capital(4.84M)15.66M(26.47M)(311K)(35.02M)
Accounts Receivables(12.16M)(8.55M)(6.59M)(917K)(26.2M)
Inventory11.57M(7.22M)7.4M5.28M(10.58M)
Accounts Payables(1.6M)(863K)(773K)(7.45M)1.13M
Other Working Capital(2.65M)32.29M(26.51M)2.77M636.96K
Other Non-Cash Items222.88M35.89M41.31M(38.9M)42.73M
Operating Cash Flow(153.62M)(88.95M)(42.84M)18.84M26.32M
Capital Expenditures(12.26M)(5.03M)(3.42M)(13.15M)(26.17M)
Acquisitions (Net)0005.71M2.9M
Purchases of Investments(230M)(271.38M)(608.25M)(8.34M)(59.44M)
Sales of Investments215.3M268.87M532.84M181.9M5.15M
Other Investing Activities(3.06M)4.12M18.42M8.41M0
Investing Cash Flow(28.9M)(1.84M)(59.5M)175.15M(77.9M)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased0000(9.91M)
Dividends Paid00000
Other Financing Activities(13.44M)(2.9M)(1.03M)(1.23M)(10.34M)
Financing Cash Flow(13.44M)(2.9M)(1.03M)(1.23M)(20.25M)
Effect of Forex Changes4.91M(28.64M)8.01M(3.25M)3.89M
Net Change in Cash(191.05M)(122.33M)(95.35M)189.51M(67.94M)
Free Cash Flow(165.88M)(93.98M)(46.26M)5.69M151.61K

Cronos Group Inc.

NASDAQ:CRON

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.